Abstract
The International Breast Cancer Study Group (IBCSG) has been conducting large, phase III clinical trials since 1978. Prior to 1986, these activities were carried out under the name of Ludwig Breast Cancer Study Group. Seven trials of adjuvant therapies are currently open for patient accrual, five of which are described in this report. The IBCSG has been a leader in the field of tailored treatment approaches for specific subpopulations of patients with breast cancer, believing that what is best for the majority may not be best for a defined minority.
Original language | English |
---|---|
Pages (from-to) | 252-254 |
Number of pages | 3 |
Journal | Breast Cancer Research |
Volume | 7 |
Issue number | 6 |
DOIs | |
Publication status | Published - Dec 2005 |
ASJC Scopus subject areas
- Cancer Research
- Oncology